Emotional Liberation is not a concept. It is a method – one that the research is catching up to.
The ACE study established a direct link between unresolved emotional experience and long-term physical and mental health outcomes. What doesn’t get processed doesn’t disappear. It reorganises. A 2023 meta-analysis of 61 randomised controlled trials found that practices integrating intentional movement with inner awareness consistently reduce difficult emotional states across diverse populations, pointing toward the body as the missing piece in most conventional treatment.
The neuroscience of trauma confirms what this method has always held: that patterns don’t live in the mind alone. They live in the nervous system, in the tissues, in the body’s learned responses to threat and overwhelm. Talking about them is rarely enough.
But the evidence base is only part of the picture. Emotional Liberation draws equally on yogic science and esoteric teachings and practices that have understood the architecture of human suffering and healing for thousands of years. The chakras, the nadis, the energetic body. Systems of inner knowledge that predate the randomized controlled trial by millennia, and that point toward the same truths the research is now beginning to confirm.
My role is to hold both: the peer-reviewed and the ancient, and bring them to bear on the very specific, very human experience of the person in front of me.
Journal of psychiatry and psychiatric disordersTrauma, Stress, and Mental Health Outcomes
Trauma and chronic stress alter amygdala and hippocampal function, impairing emotional regulation and threat discrimination.
A review of how trauma and chronic stress cause lasting mental health harm through biological pathways including HPA axis dysregulation, brain changes, epigenetic modifications, and immune activation — with outcomes shaped by social support, resilience, and access to care.
Read the study →ACS pharmacology & translational sciencePsilocybin enhances cued fear extinction and extinction recall in stress-naive, acutely stressed, and chronically stressed subjects
Psilocybin enhanced the brain’s ability to unlearn fear responses across stress-naive, acutely stressed, and chronically stressed conditions, suggesting it may support fear processing even in individuals with trauma or chronic stress histories.
A preclinical study tested psilocybin's effect on fear extinction across three stress conditions in mice: no stress, acute stress (a PTSD model), and chronic stress. Psilocybin enhanced fear extinction and extinction recall across all conditions, suggesting its potential to help the brain unlearn fear responses even under chronic or traumatic stress -- with direct relevance to PTSD and anxiety treatment.
Read the study →Journal of PsychopharmacologyInvestigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial
Single 25mg dose well tolerated, rapid and durable improvement in PTSD symptoms out to 12 weeks. No serious adverse events.
Psilocybin at a dose of 25 mg, administered with psychological support, may be safe, well-tolerated and associated with symptomatic improvement in adults with PTSD.
Read the study →Incannex HealthcareIncannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder.
73 participants, randomized double-blind placebo-controlled. Statistically significant improvements across all primary and secondary endpoints. No serious adverse events.
A Phase 2 randomized, double-blind, placebo-controlled trial of 73 adults with moderate to severe generalised anxiety disorder found that psilocybin-assisted therapy (PSX-001) delivered statistically significant improvements across every key endpoint, including anxiety, mood, disability, and quality of life — positioning it as a leading psilocybin therapy in development for GAD.
Read the study →medRxiv preprintPsilocybin treatment for symptoms of depression: a living systematic review, meta-analysis, and data resource
Study suggests that psilocybin-assisted therapy results in substantial decreases in depressive symptoms across studies to date.
Depression is a major cause of disability worldwide, motivating substantial interest in psilocybin as a potential treatment.
Read the study →Journal of affective disordersThe efficacy of psychotherapeutic interventions for prolonged grief disorder: A systematic review
A systematic review of 30 RCTs found that psychotherapeutic interventions for prolonged grief disorder produce meaningful improvements, with experiential approaches combining exposure, EMDR, and mindfulness showing particular promise for trauma-related grief — pointing toward the need for personalized, body-inclusive treatment models
A systematic review of 30 randomized controlled trials (2011-2024) examining treatments for Prolonged Grief Disorder (PGD) -- a newly recognized diagnosis in ICD-11 and DSM-5-TR affecting between 9.8% and 34.3% of bereaved people. CBT emerged as the most effective and versatile approach. Innovations combining CBT with mindfulness, exposure therapy, or EMDR showed particular promise for trauma-related grief. Alternative interventions including music therapy and Accelerated Resolution Therapy showed potential but require further research. The authors note limited generalizability due to predominantly white, female, high-income study samples.
Read the study →